CGH
VIVO

Crossmark Global Holdings’s Meridian Bioscience Inc VIVO Stock Holding History

Crossmark Global Holdings’s Portfolio VIVO Stock Details VIVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-28,820
Closed -$554K – 1493
2021
Q3 		$554K Sell
28,820
-30
-0.1% -$598 0.01% 874
2021
Q2 		$640K Buy
28,850
+10
+0% +$212 0.02% 798
2021
Q1 		$757K Buy
28,840
+560
+2% +$13.3K 0.02% 704
2020
Q4 		$529K Buy
+28,280
New +$528K 0.01% 825

Other funds holding VIVO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VLKIM
Van Lanschot Kempen Investment Management Amsterdam, Netherlands $11.4B AUM 16.77% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
SFM
Systematic Financial Management Teaneck, New Jersey $4.36B AUM 40.56% 1-Year Est. Return

Crossmark Global Holdings's VIVO Position: Q4 2021 in Review

Crossmark Global Holdings sold out of Meridian Bioscience Inc (VIVO) in Q4 2021, closing a stake of 28,820 shares — an estimated $554K sold.

Crossmark Global Holdings first reported a position in VIVO in Q4 2020 and held it in 4 quarters. The position peaked at $757K in Q1 2021. 180 funds tracked by Wall St. Rank hold VIVO as of Q4 2021.

  • Crossmark Global Holdings reported no remaining Meridian Bioscience Inc position as of Q4 2021 after selling out during the quarter.
  • Crossmark Global Holdings sold 28,820 Meridian Bioscience Inc shares in Q4 2021, an estimated $554K.
  • Crossmark Global Holdings first reported a position in Meridian Bioscience Inc in Q4 2020 and held it in 4 quarters.
  • Crossmark Global Holdings's Meridian Bioscience Inc position peaked at $757K in Q1 2021.
  • 180 funds tracked by Wall St. Rank held Meridian Bioscience Inc as of Q4 2021.

Based on Crossmark Global Holdings's 13F filing for Q4 2021, filed 10 Jan 2022.